New Application Scenarios for the AS01 Adjuvant: The ACI-24.060 Alzheimer’s Disease Vaccine Project
The treatment of Alzheimer’s Disease (AD) has entered the era of "Disease-Modifying Therapies" (DMTs). With the approval of anti-Aβ monoclonal antibodies (such as Lecanemab), the Amyloid Cascade Hypothesis has received clinical validation. However, the safety risks associated with ARIA (Amyloid-Related Imaging Abnormalities) in monoclonal antibody therapies, as well as their high...
0 Commenti 0 condivisioni 130 Views 0 Anteprima